TargetReceptor tyrosine-protein kinase erbB-2(Homo sapiens (Human))
Shanghai Fochon Pharmaceutical
US Patent
Shanghai Fochon Pharmaceutical
US Patent
Affinity DataIC50: 1.20nMAssay Description:To investigate whether a compound is able to inhibit the activity of EGFR and ErbB2 in cells, a mechanism-based assay using BT474 (EGFR overexpressio...More data for this Ligand-Target Pair
Affinity DataIC50: 1.40nMAssay Description:To investigate whether a compound is able to inhibit the activity of EGFR and ErbB2 in cells, a mechanism-based assay using BT474 (EGFR overexpressio...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2(Homo sapiens (Human))
Shanghai Fochon Pharmaceutical
US Patent
Shanghai Fochon Pharmaceutical
US Patent
Affinity DataIC50: 1.5nMAssay Description:To investigate whether a compound is able to inhibit the activity of EGFR and ErbB2 in cells, a mechanism-based assay using BT474 (EGFR overexpressio...More data for this Ligand-Target Pair
Affinity DataIC50: 1.60nMAssay Description:To investigate whether a compound is able to inhibit the activity of EGFR and ErbB2 in cells, a mechanism-based assay using BT474 (EGFR overexpressio...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2(Homo sapiens (Human))
Shanghai Fochon Pharmaceutical
US Patent
Shanghai Fochon Pharmaceutical
US Patent
Affinity DataIC50: 1.60nMAssay Description:To investigate whether a compound is able to inhibit the activity of EGFR and ErbB2 in cells, a mechanism-based assay using BT474 (EGFR overexpressio...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2(Homo sapiens (Human))
Shanghai Fochon Pharmaceutical
US Patent
Shanghai Fochon Pharmaceutical
US Patent
Affinity DataIC50: 1.60nMAssay Description:To investigate whether a compound is able to inhibit the activity of EGFR and ErbB2 in cells, a mechanism-based assay using BT474 (EGFR overexpressio...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2(Homo sapiens (Human))
Shanghai Fochon Pharmaceutical
US Patent
Shanghai Fochon Pharmaceutical
US Patent
Affinity DataIC50: 1.90nMAssay Description:To investigate whether a compound is able to inhibit the activity of EGFR and ErbB2 in cells, a mechanism-based assay using BT474 (EGFR overexpressio...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:To investigate whether a compound is able to inhibit the activity of EGFR and ErbB2 in cells, a mechanism-based assay using BT474 (EGFR overexpressio...More data for this Ligand-Target Pair
Affinity DataIC50: 2.30nMAssay Description:To investigate whether a compound is able to inhibit the activity of EGFR and ErbB2 in cells, a mechanism-based assay using BT474 (EGFR overexpressio...More data for this Ligand-Target Pair
Affinity DataIC50: 2.70nMAssay Description:To investigate whether a compound is able to inhibit the activity of EGFR and ErbB2 in cells, a mechanism-based assay using BT474 (EGFR overexpressio...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2(Homo sapiens (Human))
Shanghai Fochon Pharmaceutical
US Patent
Shanghai Fochon Pharmaceutical
US Patent
Affinity DataIC50: 2.80nMAssay Description:To investigate whether a compound is able to inhibit the activity of EGFR and ErbB2 in cells, a mechanism-based assay using BT474 (EGFR overexpressio...More data for this Ligand-Target Pair
Affinity DataIC50: 2.90nMAssay Description:To investigate whether a compound is able to inhibit the activity of EGFR and ErbB2 in cells, a mechanism-based assay using BT474 (EGFR overexpressio...More data for this Ligand-Target Pair
Affinity DataIC50: 2.90nMAssay Description:To investigate whether a compound is able to inhibit the activity of EGFR and ErbB2 in cells, a mechanism-based assay using BT474 (EGFR overexpressio...More data for this Ligand-Target Pair
Affinity DataIC50: 2.90nMAssay Description:To investigate whether a compound is able to inhibit the activity of EGFR and ErbB2 in cells, a mechanism-based assay using BT474 (EGFR overexpressio...More data for this Ligand-Target Pair
Affinity DataIC50: 3.90nMAssay Description:To investigate whether a compound is able to inhibit the activity of EGFR and ErbB2 in cells, a mechanism-based assay using BT474 (EGFR overexpressio...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2(Homo sapiens (Human))
Shanghai Fochon Pharmaceutical
US Patent
Shanghai Fochon Pharmaceutical
US Patent
Affinity DataIC50: 4.60nMAssay Description:To investigate whether a compound is able to inhibit the activity of EGFR and ErbB2 in cells, a mechanism-based assay using BT474 (EGFR overexpressio...More data for this Ligand-Target Pair
Affinity DataIC50: 4.80nMAssay Description:To investigate whether a compound is able to inhibit the activity of EGFR and ErbB2 in cells, a mechanism-based assay using BT474 (EGFR overexpressio...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2(Homo sapiens (Human))
Shanghai Fochon Pharmaceutical
US Patent
Shanghai Fochon Pharmaceutical
US Patent
Affinity DataIC50: 5nMAssay Description:To investigate whether a compound is able to inhibit the activity of EGFR and ErbB2 in cells, a mechanism-based assay using BT474 (EGFR overexpressio...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2(Homo sapiens (Human))
Shanghai Fochon Pharmaceutical
US Patent
Shanghai Fochon Pharmaceutical
US Patent
Affinity DataIC50: 5nMAssay Description:To investigate whether a compound is able to inhibit the activity of EGFR and ErbB2 in cells, a mechanism-based assay using BT474 (EGFR overexpressio...More data for this Ligand-Target Pair
Affinity DataIC50: 5.80nMAssay Description:To investigate whether a compound is able to inhibit the activity of EGFR and ErbB2 in cells, a mechanism-based assay using BT474 (EGFR overexpressio...More data for this Ligand-Target Pair
Affinity DataIC50: 6.60nMAssay Description:To investigate whether a compound is able to inhibit the activity of EGFR and ErbB2 in cells, a mechanism-based assay using BT474 (EGFR overexpressio...More data for this Ligand-Target Pair
Affinity DataIC50: 7.80nMAssay Description:To investigate whether a compound is able to inhibit the activity of EGFR and ErbB2 in cells, a mechanism-based assay using BT474 (EGFR overexpressio...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2(Homo sapiens (Human))
Shanghai Fochon Pharmaceutical
US Patent
Shanghai Fochon Pharmaceutical
US Patent
Affinity DataIC50: 8.10nMAssay Description:To investigate whether a compound is able to inhibit the activity of EGFR and ErbB2 in cells, a mechanism-based assay using BT474 (EGFR overexpressio...More data for this Ligand-Target Pair
Affinity DataIC50: 9.5nMAssay Description:To investigate whether a compound is able to inhibit the activity of EGFR and ErbB2 in cells, a mechanism-based assay using BT474 (EGFR overexpressio...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2(Homo sapiens (Human))
Shanghai Fochon Pharmaceutical
US Patent
Shanghai Fochon Pharmaceutical
US Patent
Affinity DataIC50: 9.60nMAssay Description:To investigate whether a compound is able to inhibit the activity of EGFR and ErbB2 in cells, a mechanism-based assay using BT474 (EGFR overexpressio...More data for this Ligand-Target Pair
Affinity DataIC50: 10.8nMAssay Description:To investigate whether a compound is able to inhibit the activity of EGFR and ErbB2 in cells, a mechanism-based assay using BT474 (EGFR overexpressio...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2(Homo sapiens (Human))
Shanghai Fochon Pharmaceutical
US Patent
Shanghai Fochon Pharmaceutical
US Patent
Affinity DataIC50: 11.2nMAssay Description:To investigate whether a compound is able to inhibit the activity of EGFR and ErbB2 in cells, a mechanism-based assay using BT474 (EGFR overexpressio...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2(Homo sapiens (Human))
Shanghai Fochon Pharmaceutical
US Patent
Shanghai Fochon Pharmaceutical
US Patent
Affinity DataIC50: 11.2nMAssay Description:To investigate whether a compound is able to inhibit the activity of EGFR and ErbB2 in cells, a mechanism-based assay using BT474 (EGFR overexpressio...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2(Homo sapiens (Human))
Shanghai Fochon Pharmaceutical
US Patent
Shanghai Fochon Pharmaceutical
US Patent
Affinity DataIC50: 11.8nMAssay Description:To investigate whether a compound is able to inhibit the activity of EGFR and ErbB2 in cells, a mechanism-based assay using BT474 (EGFR overexpressio...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2(Homo sapiens (Human))
Shanghai Fochon Pharmaceutical
US Patent
Shanghai Fochon Pharmaceutical
US Patent
Affinity DataIC50: 13.5nMAssay Description:To investigate whether a compound is able to inhibit the activity of EGFR and ErbB2 in cells, a mechanism-based assay using BT474 (EGFR overexpressio...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2(Homo sapiens (Human))
Shanghai Fochon Pharmaceutical
US Patent
Shanghai Fochon Pharmaceutical
US Patent
Affinity DataIC50: 14.2nMAssay Description:To investigate whether a compound is able to inhibit the activity of EGFR and ErbB2 in cells, a mechanism-based assay using BT474 (EGFR overexpressio...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2(Homo sapiens (Human))
Shanghai Fochon Pharmaceutical
US Patent
Shanghai Fochon Pharmaceutical
US Patent
Affinity DataIC50: 15.5nMAssay Description:To investigate whether a compound is able to inhibit the activity of EGFR and ErbB2 in cells, a mechanism-based assay using BT474 (EGFR overexpressio...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2(Homo sapiens (Human))
Shanghai Fochon Pharmaceutical
US Patent
Shanghai Fochon Pharmaceutical
US Patent
Affinity DataIC50: 15.6nMAssay Description:To investigate whether a compound is able to inhibit the activity of EGFR and ErbB2 in cells, a mechanism-based assay using BT474 (EGFR overexpressio...More data for this Ligand-Target Pair
Affinity DataIC50: 17.5nMAssay Description:To investigate whether a compound is able to inhibit the activity of EGFR and ErbB2 in cells, a mechanism-based assay using BT474 (EGFR overexpressio...More data for this Ligand-Target Pair
Affinity DataIC50: 21.5nMAssay Description:To investigate whether a compound is able to inhibit the activity of EGFR and ErbB2 in cells, a mechanism-based assay using BT474 (EGFR overexpressio...More data for this Ligand-Target Pair
Affinity DataIC50: 21.7nMAssay Description:To investigate whether a compound is able to inhibit the activity of EGFR and ErbB2 in cells, a mechanism-based assay using BT474 (EGFR overexpressio...More data for this Ligand-Target Pair
Affinity DataIC50: 22.2nMAssay Description:To investigate whether a compound is able to inhibit the activity of EGFR and ErbB2 in cells, a mechanism-based assay using BT474 (EGFR overexpressio...More data for this Ligand-Target Pair
Affinity DataIC50: 25nMAssay Description:To investigate whether a compound is able to inhibit the activity of EGFR and ErbB2 in cells, a mechanism-based assay using BT474 (EGFR overexpressio...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2(Homo sapiens (Human))
Shanghai Fochon Pharmaceutical
US Patent
Shanghai Fochon Pharmaceutical
US Patent
Affinity DataIC50: 32.8nMAssay Description:To investigate whether a compound is able to inhibit the activity of EGFR and ErbB2 in cells, a mechanism-based assay using BT474 (EGFR overexpressio...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2(Homo sapiens (Human))
Shanghai Fochon Pharmaceutical
US Patent
Shanghai Fochon Pharmaceutical
US Patent
Affinity DataIC50: 39.5nMAssay Description:To investigate whether a compound is able to inhibit the activity of EGFR and ErbB2 in cells, a mechanism-based assay using BT474 (EGFR overexpressio...More data for this Ligand-Target Pair